Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.83 |
| ▸ | STAT1 | P42224 | 1/20 | 0.83 |
| ▸ | TOP1 | P11387 | 4/20 | 0.47 |
| ▸ | CYCS | P99999 | 3/20 | 0.46 |
| ▸ | TERT | O14746 | 4/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29585686 | 1.00 | STAT3 (0.83) | STAT3STAT1TOP1CYCSTERT | |
| SCHEMBL30753635 | 0.95 | STAT3 (0.86) | STAT3STAT1TOP1CYCSTERT | |
| SCHEMBL30293296 | 0.95 | STAT3 (0.86) | STAT3STAT1TOP1CYCSTERT | |
| SCHEMBL1224432 | 0.95 | STAT3 (0.86) | STAT3STAT1TOP1CYCSTERT | |
| SCHEMBL31550992 | 0.95 | STAT3 (0.86) | STAT3STAT1TOP1CYCSTERT | |
| SCHEMBL473158 | 0.95 | STAT3 (0.86) | STAT3STAT1TOP1CYCSTERT | |
| SCHEMBL2563180 | 0.95 | STAT3 (0.91) | STAT3STAT1TOP1CYCSTERT | |
| SCHEMBL6027584 | 0.94 | STAT3 (0.74) | STAT3STAT1TOP1CYCSTERT | |
| SCHEMBL31324939 | 0.94 | STAT3 (0.84) | STAT3STAT1TOP1CYCSTERT | |
| SCHEMBL1275381 | 0.94 | STAT3 (0.84) | STAT3STAT1TOP1CYCSTERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119454945-A | Ultrasonic activated carrier-free nano-drug and preparation method and application thereof | 浙江大学 | 2025-02-18 | — | — | CN | claimed |
| CN-107219280-A | A kind of Metalloporphyrins gas sensor element and its preparation method and application | 济南大学 | 2017-09-29 | — | — | CN | claimed |
| US-6825343-B2 | REFLUXING TETRACYANOETHYLENE OXIDE WITH TETRAPHENYLPORPHYRIN TO FORM (5,10,15,20-TETRAPHENYL-2,3-(3'-DICYANO)CYCLOPROPANO -2,3-CHLORIN); MACROMOLECULE INTERMEDIATES USED AS CHELATE COMPOUNDS; PHOTOSENSITIVITY | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2004-11-30 | — | — | US | claimed |
| US-20040019201-A1 | 1,3-Dipolar cycloadditions to polypyrrolic macrocycles | MACALPINE JILL KIRSTEN (US) | 2004-01-29 | — | — | US | claimed |
| US-6620929-B1 | Condensing tetracyanoethylene oxide with porphyrins to form macromolecules such as 5,10,15,20-tetraphenyl-2,3-(3'-dicyano) cyclopropano-2,3-chlorin, used for photodynamic therapy; cyclization | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2003-09-16 | — | — | US | claimed |
| CN-119219645-B | Preparation method of substituted diphenyl porphyrin-2-formaldehyde | 湖南科技大学 | 2026-05-19 | — | — | CN | disclosed |
| CN-119899348-B | Preparation method of novel photoelectric catalyst of covalent organic framework and photoelectric catalyst thereof | 广东药科大学 | 2025-09-30 | — | — | CN | disclosed |
| WO-2025089384-A1 | PHOTOELECTRIC CONVERSION ELEMENT AND PHOTOELECTRIC CONVERSION DEVICE | キヤノン株式会社 | 2025-05-01 | — | — | WO | disclosed |
| WO-2025089409-A1 | PHOTOELECTRIC CONVERSION ELEMENT, PHOTOELECTRIC CONVERSION DEVICE, MOBILE BODY, AND BUILDING MATERIAL | キヤノン株式会社 | 2025-05-01 | — | — | WO | disclosed |
| WO-2025089411-A1 | COMPOSITION, PREPARATION METHOD FOR COMPOSITION, AND PHOTOELECTRIC CONVERSION ELEMENT | キヤノン株式会社 | 2025-05-01 | — | — | WO | disclosed |
| CN-119899348-A | Preparation method of novel photoelectric catalyst of covalent organic framework and photoelectric catalyst thereof | 广东药科大学 | 2025-04-29 | — | — | CN | disclosed |
| CN-119899348-A | Preparation method of novel photoelectric catalyst of covalent organic framework and photoelectric catalyst thereof | 广东药科大学 | 2025-04-29 | — | — | CN | disclosed |
| US-5723677-A | Method for hydroperoxide decomposition using novel porphyrins synthesized from dipyrromethanes and aldehydes | SUN COMPANY, INC. (R&M) (US) | 1998-03-03 | — | — | US | disclosed |
| US-5672717-A | ANTITUMOR AGENTS TREATING CANCER | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| US-5571908-A | Porphyrins | SUN COMPANY, INC. (R&M) (US) | 1996-11-05 | — | — | US | disclosed |
| EP-0708768-A4 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORP (US) | 1996-08-21 | — | — | EP | disclosed |
| EP-0708768-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-05-01 | — | — | EP | disclosed |
| EP-0665056-A2 | Method for oxidizing alkanes using halocarbyl-substituted porphyrins synthesized from meso-halocarbyl-dipyrromethanes and aldehydes | SUN COMPANY, INC. (R&M) (US) | 1995-08-02 | — | — | EP | disclosed |
| EP-0665230-A2 | Halocarbyl-substituted porphyrins and their synthesis from meso-halocarbyl-dipyrromethanes and aldehydes | SUN COMPANY, INC. (R&M) (US) | 1995-08-02 | — | — | EP | disclosed |
| WO-1995002591-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019201-A1 | 1,3-Dipolar cycloadditions to polypyrrolic macrocycles | DHPS, DDT, ADCYAP1R1 | STAT3 4802/4885STAT1 4772/4885TOP1 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.